Trial Profile
A retrospective study evaluating predictive risk factors for kidney transplant recipients with low immunologic risk of acute rejection subjected to immunosuppressive induction therapy with Basiliximab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Nov 2016
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Mycophenolate mofetil; Prednisolone; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 14 Nov 2016 New trial record